Moody Lynn & Lieberson LLC Acquires 16,752 Shares of Novartis AG $NVS

Moody Lynn & Lieberson LLC increased its holdings in shares of Novartis AG (NYSE:NVS) by 731.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,041 shares of the company’s stock after acquiring an additional 16,752 shares during the period. Moody Lynn & Lieberson LLC’s holdings in Novartis were worth $2,442,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in Novartis by 1.7% in the 3rd quarter. Blue Trust Inc. now owns 4,763 shares of the company’s stock worth $611,000 after purchasing an additional 78 shares in the last quarter. Glenview Trust co raised its holdings in Novartis by 2.3% in the second quarter. Glenview Trust co now owns 3,800 shares of the company’s stock worth $460,000 after buying an additional 84 shares during the last quarter. Essex Savings Bank lifted its stake in shares of Novartis by 1.9% in the second quarter. Essex Savings Bank now owns 4,611 shares of the company’s stock worth $558,000 after buying an additional 85 shares in the last quarter. Physician Wealth Advisors Inc. grew its holdings in shares of Novartis by 5.8% during the second quarter. Physician Wealth Advisors Inc. now owns 1,541 shares of the company’s stock valued at $186,000 after buying an additional 85 shares during the last quarter. Finally, Deroy & Devereaux Private Investment Counsel Inc. increased its position in shares of Novartis by 4.4% during the second quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 2,062 shares of the company’s stock valued at $250,000 after acquiring an additional 87 shares in the last quarter. 13.12% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NVS. Cfra set a $126.00 price objective on Novartis and gave the company a “hold” rating in a research report on Wednesday, October 29th. HC Wainwright lowered Novartis to a “neutral” rating in a report on Monday, October 27th. JPMorgan Chase & Co. upgraded shares of Novartis from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Bank of America upgraded shares of Novartis from a “neutral” rating to a “buy” rating in a research report on Tuesday, November 25th. Finally, Wall Street Zen raised shares of Novartis from a “hold” rating to a “buy” rating in a report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $119.75.

Novartis Price Performance

NYSE:NVS opened at $138.75 on Wednesday. The business’s 50-day moving average is $130.87 and its 200 day moving average is $125.82. Novartis AG has a 12 month low of $96.91 and a 12 month high of $140.18. The company has a market capitalization of $293.09 billion, a P/E ratio of 18.95, a P/E/G ratio of 1.97 and a beta of 0.52. The company has a current ratio of 0.88, a quick ratio of 0.68 and a debt-to-equity ratio of 0.50.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing the consensus estimate of $2.26 by ($0.01). The firm had revenue of $14.36 billion for the quarter, compared to analysts’ expectations of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.06 EPS. On average, equities research analysts forecast that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.